The chronic subcutaneous administration of Ex-4 attenuates the peripheral symptoms of type 2 diabetes in rats, including hyperglycemia and IR, and enhances the levels of brain cortical GLP-1 and insulin-like growth factor (IGF)-1 and their downstream signaling pathways. This evidence concerns the gene GCG and type 2 diabetes mellitus.